Strategic Partnerships Active collaborations with Illumina and Thermo Fisher Scientific, plus recent Pirche Ag partnership, indicate a strong channel and co-development potential. Leverage these relationships to position Devyser kits for integrated workflows, expanded adoption in transplant and oncology diagnostics, and joint marketing initiatives to reach new labs.

Expansion Footprint Customer base spans more than 60 countries with routine diagnostics in laboratories, suggesting expansive international sales opportunities. Focus on regions with growing oncology and prenatal diagnostics demand, and offer scalable kits compatible with diverse regulatory and workflow environments.

Product Roadmap Recent launches like LynchFAP, BRCA PALB2, and long-range PCR capability demonstrate a robust R&D pipeline addressing complex DNA testing. Use this to upsell current customers on enhanced panels and to target labs needing comprehensive hereditary and transplant diagnostics with differentiated accuracy.

Clinical Provenance Evidence of dd-cfDNA detection in dual donor kidney transplants and routine diagnostics suitability underscores reliability. Build credibility with labs seeking regulatory-compliant, reproducible workflows and advocate for adoption in high-stakes oncology and transplantation settings.

Tech-Enabled Reliability Tech stack and a strong emphasis on simplicity and error reduction indicate smooth integration with existing lab IT ecosystems. Position Devyser as a compatible solution for labs investing in digitalization, analytics, and compliant data workflows using partners like AWS, HubSpot, and OneTrust.